AcouSort selected by EIC for participation in leading medical exhibition
AcouSort has been selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO2022 after a highly competitive evaluation process. AcouSort is thus one of 20 European companies selected by EU for full sponsorship at America’s leading medical exhibition, taking place in San Diego June 13-16.
– It is of course incredibly inspiring to be one of the 20 European SMEs or startups selected by EIC for participation at BIO2022. We see this as one of the most important conferences in the healthcare and biotech industry, where most leading companies are represented, says AcouSort’s CEO Torsten Freltoft.
During the convention, AcouSort will mainly focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and personalized medicine such as novel cancer therapies.
The 2022 BIO International Convention will feature more than 100 interactive sessions across 4 days covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, next-generation biotherapeutics, and the latest updates from industry experts on COVID-19 and the vaccines. The delegation of the European Pavilion was selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business out of their participation.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.